Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization

The technology includes patent rights and related materials for live attenuated viruses that can be used as a prophylactic vaccine against respiratory syncytial virus. The viruses are generated using codon-pair deoptimization techniques, resulting in attenuation based on hundreds or thousands of nucleotide substitutions with no differences at the amino acid level. Various permutations are based on deoptimization of the RSV polymerase ORF, the F and G glycoprotein ORFs, the NS1, NS2, N, P, M, and SH ORFs, or all of these in combination. Experimental growth data for representative viruses in mice and in African Green Monkeys demonstrated in vivo growth attenuation.

Potential Commercial Applications: Competitive Advantages:
  • Prophylactic vaccine
  • Childhood vaccine
  • Live attenuated
  • Codon deoptimized

Peter Collins (NIAID)
Cyril Le Nouen (NIAID)
Linda Brock (NIAID)
Ursula Buchholz (NIAID)
Joshua DiNapoli (NIAID)
Steffen Mueller
Eckard Wimmer

Intellectual Property:
US Application No. 61/762,768
US Application No. 61/794,155

Collins PL, Melero JA. PMID 21963675
Coleman JR, et al. PMID 18583614

Licensing Contact:
Michael Shmilovich , Esq.
NIH Office of Technology Transfer
Phone: 301-435-5019

OTT Reference No: E-080-2013/0

Updated: Jun-06-2013